![]() | ![]() |
Formats:
|
||||||||||||||
Copyright © 2003, The National Academy of
Sciences Genetics Protein–DNA interaction mapping using genomic tiling path
microarrays in Drosophila *Department of Genetics and †Biostatistics Division, Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT 06520; ‡Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands; and §Chromatin and Cell Biology Laboratory, Institute of Human Genetics, Centre National de la Recherche Scientifique, 34396 Montpellier, Cedex 5, France ¶
To whom correspondence may be addressed. E-mail:
b.v.steensel/at/nki.nl
or
kevin.white/at/yale.edu.
Communicated by Walter J. Gehring, University of Basel, Basel,
Switzerland, June 4, 2003 Received November 11, 2002. This article has been cited by other articles in PMC.Abstract We demonstrate the use of a chromosomal walk (or “tiling path”)
printed as DNA microarrays for mapping protein–DNA interactions across
large regions of contiguous genomic DNA in Drosophila melanogaster.
Microarrays were constructed with genomic DNA fragments 430–920 bp in
length, covering 2.9 million base pairs of the
Adh–cactus region of chromosome 2 and 85,000 base
pairs of the 82F region of chromosome 3. We performed DNA
localization mapping for the heterochromatin protein HP1 and for the
sequence-specific GAGA transcription factor, producing a comprehensive,
high-resolution map of in vivo protein–DNA interactions
throughout these regions of the Drosophila genome. The Drosophila model has served as a guidepost for working out the
molecular genetics of gene expression regulation in a developmental context,
and the availability of the complete Drosophila melanogaster genome
sequence has presented a new challenge: to systematically decode the genome
into regulatory networks that direct complex developmental processes. This
decoding will be accelerated through the use of gene expression and
protein–DNA interaction data to map transcriptional regulatory networks
on a genome-wide scale (1), but
the appropriate technologies must be developed for such mapping to be
efficient and comprehensive. DNA microarrays have been used to study gene
expression patterns genome-wide during developmental processes in
Drosophila, Caenorhabditis elegans, and mouse
(2–7).
Methodologies to map protein–DNA interactions using cDNA microarrays
have also been developed in Drosophila
(8). However, the most
extensive protein–DNA interaction mapping has been carried out in yeast,
where DNA microarrays containing all intergenic regions of the genome have
been used to systematically identify the binding sites of transcription
factors
(9–11).
In these studies, chromatin immunoprecipitation (ChIP) was used to isolate
protein–DNA complexes, and the resulting purified DNA was labeled and
hybridized to the intergenic DNA microarrays. Recently, ChIP has been used
with human DNA microarrays to identify binding sites of GATA-1 in the 75-kb
sequence of the β-globin locus and binding sites of E2F in promoters of
genes expressed during cell cycle entry
(12–14).
The results from yeast demonstrate that intergenic arrays can be extremely
valuable for the study of transcriptional regulatory networks, and the results
from human show that, in principle, the technology can be applied to study
complex genetic loci. Here we demonstrate the use of genomic DNA tiling path microarrays to map
protein–DNA interactions at high resolution along large segments of
genomic DNA from D. melanogaster. We used DNA microarrays tiled
across two genomic regions: 2.9 Mbp of Adh–cactus
region on chromosome 2 and 85 kb of 82F region on chromosome 3. These
arrays allowed us to assay protein–DNA interactions in coding and
noncoding genomic sequence that contains at least 220 genes
(15–18).
The arrays were composed of overlapping fragments with sizes of 850–920
bp each across the Adh–cactus region and 430–500
bp each across the 82F region. To map protein–DNA interactions,
we used the DamID chromatin profiling technique
(8,
19). This technique involves
in vivo expression of a trace amount of a chromatin protein of
interest fused to Escherichia coli DNA adenine methyltransferase
(Dam). As a result, DNA in the target loci of the chromatin protein is
preferentially methylated by the tethered Dam. Subsequently, methylated DNA
fragments are purified, labeled with a fluorescent dye, and hybridized to a
microarray. To correct for unspecific binding of Dam and local differences in
DNA accessibility, methylated DNA fragments of control cells transfected with
Dam alone are labeled with a different fluorescent dye and cohybridized. The
obtained ratio of fluorescent dyes reflects the extent of protein binding to
the probed DNA sequence
(8). We performed high-resolution binding site mapping of a sequence-specific
DNA-binding factor, GAF (20),
and the heterochromatin protein HP1
(21). Binding profiles of both
proteins have previously been determined in a study using cDNA arrays
containing ≈300 cDNA fragments
(8). Only binding sites in the
immediate vicinity of transcribed regions can be detected by using cDNA
arrays. However, localization of chromatin-associated proteins is often
distant from transcribed regions. Here we demonstrate that genomic tiling path
arrays can be used for comprehensive and high-resolution mapping of
chromatin-associated proteins in the Drosophila genome. We discovered
dozens of new GAF-binding sites in the 3 Mb of genomic DNA surveyed, and we
were able to initially map these sites to a few hundred base pairs in most
cases. The use of computational sequence analysis methods allowed many sites
of chromosomal association to be pinpointed to within several nucleotides.
Furthermore, ChIP analyses verified several randomly selected sites identified
through this analysis, providing validation by using an independent method for
direct mapping of GAF–DNA interactions. In addition to the
high-resolution mapping of GAF protein, we found new patterns of HP1
association with transposable elements throughout this region of the
genome. Materials and Methods DNA Array Construction. To create the initial set of test arrays
reported in this study, primers were designed to amplify 3,648 fragments
representing the 2.9-Mb Adh–cactus region (on
chromosome 2L) and 192 fragments covering 85 kb of the 82F region (on
chromosome 3R) (Fig. 1 a and
b
DamID. The DamID procedure was performed in Drosophila
Kc167 cells as described (8,
19), except that methylated
DNA fragments were not obtained by DpnI digestion and subsequent
sucrose gradient centrifugation, but selectively amplified by PCR. Genomic DNA isolated from Kc167 cells transfected with Dam or a Dam-fusion
protein was isolated as described
(8). In brief,
≈108 cells from one 10-cm plate were collected, pelleted, and
resuspended in 1 ml of ice-cold T10E10 (10 mM
Tris·HCl,pH7.5/10 mM EDTA). One milliliter of freshly prepared TENSK
buffer [100 mM NaCl/0.5% SDS/200 μl of Proteinase K (Roche Molecular
Biochemicals) in T10E10] was added and mixed by
inversion. After incubation for 2 h at 55°C, 2.0 ml of buffer-saturated
phenol/chloroform/isoamylalcohol was added, followed by mixing by inversion
and spinning for 10 min at 3.5 krpm. The water phase was transferred to 2.0 ml
of isopropanol and 0.2 ml of 3 M sodium acetate (pH 5.2), and mixed; the DNA
was recovered by spooling on a yellow tip, completely dissolved in 0.3 ml of
T10E10 with 2 μg of DNase-free RNase (Roche Molecular
Biochemicals), and incubated at 37°C for at least 1 h. Next, 0.3 ml of
TENSK was added, followed by incubation for 30 min at 55°C. A second
phenolchloroform extraction followed, after which the water phase was
transferred to 0.6 ml of isopropanol and 60 μl of 3 M sodium acetate (pH
5.2). The solution was mixed by inversion and the DNA precipitate was
recovered, rinsed in 70% ethanol, and dissolved in 50 μl of
T10E10 by incubation at 37°C for several hours. For selective PCR amplication of methylated DNA fragments, 40 μg of the
isolated genomic DNA was digested for 16 h at 37°C with 40 units of
DpnI (New England Biolabs) in the presence of 12.5 ng of DNase-free
RNase A (Roche Molecular Biochemicals) in a total volume of 50 μl of buffer
4 (New England Biolabs). After inactivation of DpnI at 80°C for
20 min, 4 μg of the DpnI-digested genomic DNA was ligated to 40
pmol of a double-stranded unphosphorylated adaptor (top strand:
5′-CTAATACGACTCACTATAGGGCAGCGTGGTCGCGGCCGAGGA-3′, bottom strand:
5′-TCCTCGGCCG-3′) for 2 h at 16°C with 5 units of T4-Ligase
(Roche Molecular Biochemicals) in a total volume of 20 μl of ligation
buffer. To prevent amplification of DNA fragments containing unmethylated
GATCs, 1 μg of the adaptor-ligated DNA was cut with 2 units of
DpnII (New England Biolabs) for1hat37°C in a total volume of 20
μl of DpnII buffer. Next, amplification was performed by using 0.5
μg of DpnII-cut DNA, 1 μl of Advantage cDNA PCR polymerase mix
(CLONTECH), 10 nmol of each dATP, dCTP, dGTP, and dTTP, and 62.5 pmol of
primer (5′-GGTCGCGGCCGAGGATC-3′) in 50 μl total volume of
Advantage PCR buffer, under the following cycling conditions: activation of
the polymerase and nick translation for 10 min at 68°C, followed by one
cycle of 1 min at 94°C, 5 min at 65°C and 15 min at 68°C; 3 cycles
of 1 min at 94°C, 1 min at 65°C and 10 min at 68°C; and 14 cycles
of 1 min at 94°C, 1 min at 65°C and 2 min at 68°C. The PCR
products were purified by using the QIAquick PCR purification kit (Qiagen) and
labeled with Cy3 or Cy5 as described
(8). Finally, labeled experimental (Dam–protein fusion) and reference
(Dam) DNA samples were mixed and hybridized to microarrays in 3× SSC
(450 mM sodium chloride/45 mM sodium citrate, pH 7.0) supplemented with 0.22%
SDS, 20 μg of poly(dA–dT), 100 μg of yeast tRNA, and 25 μg of
unlabeled DpnI-digested plasmid encoding the fusion protein used for
transfection. After a 15-min incubation at 42°C, hybridization was
performed at 63°C for 16 h, followed by a sequential washing at room
temperature in 1.14× SSC plus 0.0285% SDS, 1.14× SSC, 0.228×
SSC, and 0.057× SSC. Immediately after washing, arrays were spun dry at
1,000 × g for 5 min in a table-top centrifuge. Motif Analysis. Consensus binding motifs were inferred from the
complete set of binding log-ratios by using three different algorithms: the
motif-based linear regression method REDUCE, which exploits the correlation
between the occurrence of sequence motifs near exons of genes and the
expression of those exons
(23), the method proposed by
Keles et al. (24),
which is conceptually similar to REDUCE, but uses a different motif selection
scheme, and the MDscan method, which uses a modified Gibbs sampling strategy
to search for common patterns in the segments with high binding ratios
(25). ChIP of GAF Binding Fragments. ChIP was performed by using
formaldehyde cross-linking, and by using anti-GAF antibody with chromatin
extracts of both Kc cells and Drosophila embryos as described
(26). Primers were designed to
amplify five GAF-binding fragments identified with DamID and seven fragments
that did not show any GAF binding in the DamID experiments. However, all
fragments with GAGAG sites were selected, regardless of whether they were
positive for GAF binding in the DamID assay. PCR products were run on an
agarose gel (1.4%) and transferred to a nylon membrane for Southern blot
analysis. Blots were hybridized either with a probe made from a mock
immunoprecipitation (IP) sample or with a probe from GAF ChIP. Hybridized
membrane was then subjected to a 24-h exposure in a phosphorimager cassette,
and results were quantified as presented in
Table 2. Tested fragments were
scored as “ChIP positive” if the ratio of mock IP to GAF IP was
≥2.0 in ChIP with embryo chromatin extracts. Our positive controls (Fab7,
Mcp, and bxd from the Bithorax complex regulatory region) were enriched,
although the enrichment value in Kc167 cells is not as high as usually found
in embryos (26). We therefore
lowered the criteria for enrichment in GAF ChIP for Kc cells to 1.5-fold. ChIP
experiments were performed in duplicate.
Results Binding Site Profiling Using Tiling Path DNA Microarrays. We
designed DNA microarrays containing contiguous sequences from two different
chromosomes. A total of 2.9 Mb of the chromosomal sequences were from the
well-studied Adh–cactus region of chromosome 2L
(Fig. 1a To begin, we consider the characteristic patterns of microarray data
expected when these tiling path microarrays are used with the Dam ID
technique, which compares genomic methylation patterns in the presence of a
Dam-fusion protein to background methylation from expression of Dam alone
(19). In the simplest case,
the association of a Dam-fusion protein would occur at a single point along
the chromosome. At that point, the signal ratio from a DamID experiment
(Dam-fusion protein/Dam alone) would be high. One expects that targeted
methylation levels of DNA in either direction from that point will
progressively decrease proportional to distance, with a concomitant decease in
the signal ratio. The quantitative result from the microarray experiment will
accordingly be represented as a curve with its maximum over the point
(Fig. 1c GAF Binding Profiles. We used a local linear weighted regression
method that is more sensitive than a standard t test to identify 169
genomic DNA fragments with significantly elevated GAF-Dam/Dam methylation
ratios (see Supporting Methods and ref.
27). These fragments
congregated into 46 chromosomal areas (groups of adjacent fragments) (Table 4,
which is published as supporting information on the PNAS web site). Because
the affinity of GAF binding may be reflected in the microarray measurements,
we imposed an additional criterion of a threshold cut-off to divide the 169
significant fragments into a set that shows a >2-fold differential
(“high binding ratio”) and a set that does not (“low binding
ratio”) (all ratios >2 also were significant by using a standard
t test with P < 0.025; see Supporting Methods).
We found 54 fragments in 23 areas in the 2.9-Mb
Adh–cactus region, and 10 fragments in three areas in
the 82F region (26 areas total) that showed high GAF binding ratios
(Table 4, Fig. 2
Most of the areas in the Adh–cactus region
associated with high GAF binding ratios are within the vicinity of sequences
that contain annotated genes, with 15 that are <3 kb from the nearest start
codon, and 18 that are within 10 kb of the nearest start codon (Table 4).
Although high GAF binding ratios were commonly associated with putative
regulatory sequences 5′ or 3′ of transcription units (nine
instances), 5 of the 23 GAF binding sites are contained within 5′ or
3′ UTRs and 9 occurred within introns (Table 4). None occurred within
coding regions. There was a single instance where no annotation features were
identified in a 10-kb vicinity of GAF binding (the closest gene was >25 kb
away). This may be caused by regulatory sequences acting from a distance, it
may be caused by functionally irrelevant GAF binding, or it may be caused by
the existence of genes not yet annotated. Considering the
Adh–cactus and 82F regions as representative
samples from the genome, and extrapolating from these results, we expect that
there are likely >1,000 sites with high GAF binding genome-wide, and
>750 more sites with low but detectable GAF binding by using the DamID
assay. GAF Binding Motif Analyses. In vitro, GAF binds to the
sequence GAGAG (28). By using
three independent motif-finding methods that all use genomic sequence data and
GAF binding data from the tiling path microarrays, we were able to
successfully identify the correct consensus GAGAG binding motif for GAF.
Table 1 shows the results of
analyses based on Regulatory Element Detection Using Correlation of Expression
(REDUCE) (23), the Keles
et al. method (24),
and the Motif Discovery scan (MDscan)
(25). The first two methods
are similar; they were developed to perform motif selection based on a
least-squares fit of a linear predictive model for expression log-ratios, but
can be used without modification to analyze binding log-ratios. The MDscan
method compares the probability that one motif occurs in the top ranking
sequences based on binding ratios and its occurrence in the background
sequences. The success of all three of these algorithms in identifying the
correct binding site indicates that DNA tiling path microarrays combined with
DamID mapping of binding sites will provide a robust source of data for
cis-regulatory motif-finding algorithms.
Scanning of genome sequence revealed that GAGAG/CTCTC motifs were contained
in almost all DNA fragments showing peak levels of signal in the 46 areas we
identified, but also in 2,115 DNA fragments without appreciable binding
signal. All of the areas with high levels of binding contained at least one
GAGAG/CTCTC site in the DNA fragments that showed peak signal on the
microarrays, allowing the precise coordinates of GAF binding to be predicted.
The average number of such sites in DNA fragments with peak signal was 4.3,
whereas the median was 3 sites. In the 20 areas with low levels of binding,
often more than one adjacent fragment showed indistinguishable levels of peak
signal. The average number of GAGAG/CTCTC sites in these DNA fragments was
2.2, whereas the median was 1 site. Thus, we find an overall correlation
between signal strength and the number of potential binding sites for GAF. For
one case, no GAGAG/CTCTC sites were identified even though the binding
patterns observed were monotonic and in nonrepetitive DNA sequence. This case
could be caused by weak binding site(s) that do not match the exact consensus,
or perhaps this is a false positive. Independent Verification of GAF Binding Sites Using ChIP. We
verified several candidate GAF binding sites by using ChIP from both Kc167
cell chromatin extracts and in embryonic chromatin extracts
(26). We tested five fragments
shown by DamID to bind GAF and seven fragments that were not positive in the
GAF–DamID assay. Among the five fragments that were positive for DamGAF
binding, four were from the high-level GAF-binding fragment list and one was
from the low-level GAF-binding fragment list. All of the fragments tested,
both those postive and negative for GAF binding in the DamID assay, contained
at least one copy of the GAF-binding motif (GAGAG/CTCTC)
(28). All five of the GAF DamID-positive DNA fragments also were positive for
binding in the GAF ChIP assays from both Kc167 cells and embryos
(Table 2). No difference
between DamID- and ChIP-positive GAF binding sites was noted in Kc167 cells,
and only one of the seven DamID-negative fragments was ChIP-positive in the
embryonic chromatin extracts. These results indicate that the ChIP and DamID
assays both accurately reflect bona fide GAF binding sites in vivo.
Although the correspondence between DamID and GAF assays was striking, there
was only a moderate correlation between the quantitative values of the DamID
and GAF positive data for Kc167 cells (0.54), and thus the quantitative
results from the two techniques are complementary. Finally, these results also
indicate that GAF distribution in embryos and in embryonically derived Kc167
cells is largely overlapping, but qualitatively and perhaps quantitatively
different. HP1 Binding Profile. We identified 17 areas in the 2.9 Mb
Adh–cactus region, and one area in the 150 kb
82F region, that were associated with significant Dam-HP1:Dam ratios
(Fig. 3 a and
b
We found patterns indicating real HP1 binding within the coding sequence of
only one gene, crinkled (ck), which encodes a non-muscle
myosin involved in bristle formation (Fig.
3c Finally, we compared HP1 and GAF binding sites and found that they rarely
overlapped (Fig. 4a, which is published as supporting information on
the PNAS web site). In only one case did we observe GAF and HP1 binding
profiles very near one another (Fig. 4b). These results indicate
that, on a local level, GAF and HP1 binding sites are largely independent of
one another in the Adh–cactus region. Summary. Our results demonstrate the feasibility of
protein–DNA interaction mapping with tiling path DNA microarrays that
cover large tracts of a complex genome. We found that data from genomic tiling
path arrays allowed the sites of chromosomal association to be readily
discerned for both a site-specific transcription factor and a general
heterochromatin-associated protein. Because all GAF-binding fragments
identified with DamID were verified with ChIP, either approach is capable of
yielding accurate and high-resolution binding site mapping for
chromatin-associated proteins. ChIP can be complementary to DamID, and when
suitable antibodies are available for a DNA-associated protein, ChIP can be
used either with candidate targets or with microarrays to cross-validate
binding sites. Additional studies will be required to determine the biological
relevance of the dozens of GAF and HP1 binding sites we observed.
Nevertheless, these results indicate that genomic tiling path microarrays will
be valuable for mapping the binding sites of a wide range of regulatory
proteins in Drosophila. These methods should be applied equally well
for mapping DNA–protein interactions in cells isolated from animals, and
will aid in the comprehensive delineation of genome-wide regulatory networks
that control gene expression and development. Supporting Information
Acknowledgments We thank Scott A. Rifkin for computational assistance and Harmen Bussemaker
for helpful discussions and support. This work is supported by a Human
Frontiers in Science Program grant (to B.V.S. and K.P.W.), a Centre National
de la Recherche Scientifique grant (to G.C.), a National Science Foundation
grant (to H.Z.), and a National Human Genome Research Institute grant (to
K.P.W.). Notes Abbreviations: ChIP, chromatin immunoprecipitation; Dam, DNA adenine
methyltransferase. References 1. Reinke, V. & White, K. P. (2002. ) Annu.
Rev. Genomics Hum. Genet. 3,
153–178. [PubMed] 2. White, K. P., Rifkin, S. A., Hurban, P. & Hogness, D. S.
(1999. ) Science
286,
2179–2184. [PubMed] 3. Reinke, V., Smith, H. E., Nance, J., Wang, J., Van Doren, C.,
Begley, R., Jones, S. J., Davis, E. B., Scherer, S., Ward, S. & Kim, S. K.
(2000. ) Mol. Cell
6,
605–616. [PubMed] 4. Hill, A. A., Hunter, C. P., Tsung, B. T., Tucker-Kellogg, G. &
Brown, E. L. (2000. ) Science
290,
809–812. [PubMed] 5. Jiang, M., Ryu, J., Kiraly, M., Duke, K., Reinke, V. & Kim, S.
K. (2001. ) Proc. Natl. Acad. Sci. USA
98,
218–223. [PubMed] 6. Miki, R., Kadota, K., Bono, H., Mizuno, Y., Tomaru, Y., Carninci,
P., Itoh, M., Shibata, K., Kawai, J., Konno, H., et al.
(2001. ) Proc. Natl. Acad. Sci. USA
98,
2199–2204. [PubMed] 7. Arbeitman, M. N., Furlong, E. E., Imam, F., Johnson, E., Null, B.
H., Baker, B. S., Krasnow, M. A., Scott, M. P., Davis, R. W. & White, K.
P. (2002. ) Science
297,
2270–2275. [PubMed] 8. van Steensel, B., Delrow, J. & Henikoff, S. (2001. )
Nat. Genet. 27,
304–308. [PubMed] 9. Iyer, V. R., Horak, C. E., Scafe, C. S., Botstein, D., Snyder, M.
& Brown, P. O. (2001. ) Nature
409,
533–538. [PubMed] 10. Ren, B., Robert, F., Wyrick, J. J., Aparicio, O., Jennings, E. G.,
Simon, I., Zeitlinger, J., Schreiber, J., Hannett, N., Kanin, E., et
al. (2000. ) Science
290,
2306–2309. [PubMed] 11. Lee, T. I., Rinaldi, N. J., Robert, F., Odom, D. T., Bar-Joseph,
Z., Gerber, G. K., Hannett, N. M., Harbison, C. T., Thompson, C. M., Simon,
I., et al. (2002. ) Science
298,
799–804. [PubMed] 12. Horak, C. E., Mahajan, M. C., Luscombe, N. M., Gerstein, M.,
Weissman, S. M. & Snyder, M. (2002. ) Proc. Natl.
Acad. Sci. USA 99,
2924–2929. [PubMed] 13. Ren, B., Cam, H., Takahashi, Y., Volkert, T., Terragni, J., Young,
R. A. & Dynlacht, B. D. (2002. ) Genes
Dev. 16,
245–256. [PubMed] 14. Weinmann, A. S., Yan, P. S., Oberley, M. J., Huang, T. H. &
Farnham, P. J. (2002. ) Genes Dev.
16,
235–244. [PubMed] 15. Misra, S., Crosby, M. A., Mungall, C. J., Matthews, B. B.,
Campbell, K. S., Hradecky, P., Huang, Y., Kaminker, J. S., Millburn, G. H.,
Prochnik, S. E., et al. (2002. ) Genome
Biol. 3,
RESEARCH0083-3. [PubMed] 16. Ashburner, M., Misra, S., Roote, J., Lewis, S. E., Blazej, R.,
Davis, T., Doyle, C., Galle, R., George, R., Harris, N., et al.
(1999. ) Genetics
153,
179–219. [PubMed] 17. Reese, M. G., Hartzell, G., Harris, N. L., Ohler, U., Abril, J. F.
& Lewis, S. E. (2000. ) Genome Res.
10,
483–501. [PubMed] 18. Stowers, R. S., Russell, S. & Garza, D. (1999. )
Dev. Biol. 213,
116–130. [PubMed] 19. van Steensel, B. & Henikoff, S. (2000. )
Nat. Biotechnol. 18,
424–428. [PubMed] 20. Biggin, M. D. & Tjian, R. (1988. )
Cell 53,
699–711. [PubMed] 21. James, T. C., Eissenberg, J. C., Craig, C., Dietrich, V., Hobson,
A. & Elgin, S. C. (1989. ) Eur. J. Cell
Biol. 50,
170–180. [PubMed] 22. Adams, M. D., Celniker, S. E., Holt, R. A., Evans, C. A., Gocayne,
J. D., Amanatides, P. G., Scherer, S. E., Li, P. W., Hoskins, R. A., Galle, R.
F., et al. (2000. ) Science
287,
2185–2195. [PubMed] 23. Bussemaker, H. J., Li, H. & Siggia, E. D. (2001. )
Nat. Genet. 27,
167–171. [PubMed] 24. Keles, S., Van Der Laan, M. & Eisen, M. B. (2002. )
Bioinformatics 18,
1167–1175. [PubMed] 25. Liu, X. S., Brutlag, D. L. & Liu, J. S. (2002. )
Nat. Biotechnol. 20,
835–839. [PubMed] 26. Cavalli, G., Orlando, V. & Paro, R. (1999. ) in
Chromosome Structural Analysis: A Practical Approach,
ed. Bickmore, W. A. (Oxford Univ. Press, Oxford), pp.
20–37. 27. Cleveland, W. S., Grosse, E. & Shyu, W. M. (1992. )
in Statistical Models, eds. Chambers, J. M. &
Hastie, T. J. (Brooks/Cole, Belmont, CA), pp.
309–373. 28. Omichinski, J. G., Pedone, P. V., Felsenfeld, G., Gronenborn, A. M.
& Clore, G. M. (1997. ) Nat. Struct.
Biol. 4,
122–132. [PubMed] 29. Gubb, D., Shelton, M., Roote, J., McGill, S. & Ashburner, M.
(1984. ) Chromosoma
91,
54–64. |
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||
Annu Rev Genomics Hum Genet. 2002; 3():153-78.
[Annu Rev Genomics Hum Genet. 2002]Science. 1999 Dec 10; 286(5447):2179-84.
[Science. 1999]Science. 2002 Sep 27; 297(5590):2270-5.
[Science. 2002]Nat Genet. 2001 Mar; 27(3):304-8.
[Nat Genet. 2001]Nature. 2001 Jan 25; 409(6819):533-8.
[Nature. 2001]Genome Biol. 2002; 3(12):RESEARCH0083.
[Genome Biol. 2002]Dev Biol. 1999 Sep 1; 213(1):116-30.
[Dev Biol. 1999]Nat Genet. 2001 Mar; 27(3):304-8.
[Nat Genet. 2001]Nat Biotechnol. 2000 Apr; 18(4):424-8.
[Nat Biotechnol. 2000]Cell. 1988 Jun 3; 53(5):699-711.
[Cell. 1988]Eur J Cell Biol. 1989 Oct; 50(1):170-80.
[Eur J Cell Biol. 1989]Nat Genet. 2001 Mar; 27(3):304-8.
[Nat Genet. 2001]Genetics. 1999 Sep; 153(1):179-219.
[Genetics. 1999]Science. 2000 Mar 24; 287(5461):2185-95.
[Science. 2000]Nat Genet. 2001 Mar; 27(3):304-8.
[Nat Genet. 2001]Nat Biotechnol. 2000 Apr; 18(4):424-8.
[Nat Biotechnol. 2000]Nat Genet. 2001 Mar; 27(3):304-8.
[Nat Genet. 2001]Nat Genet. 2001 Mar; 27(3):304-8.
[Nat Genet. 2001]Nat Genet. 2001 Feb; 27(2):167-71.
[Nat Genet. 2001]Bioinformatics. 2002 Sep; 18(9):1167-75.
[Bioinformatics. 2002]Nat Biotechnol. 2002 Aug; 20(8):835-9.
[Nat Biotechnol. 2002]Genetics. 1999 Sep; 153(1):179-219.
[Genetics. 1999]Genome Res. 2000 Apr; 10(4):483-501.
[Genome Res. 2000]Dev Biol. 1999 Sep 1; 213(1):116-30.
[Dev Biol. 1999]Nat Biotechnol. 2000 Apr; 18(4):424-8.
[Nat Biotechnol. 2000]Nat Struct Biol. 1997 Feb; 4(2):122-32.
[Nat Struct Biol. 1997]Nat Genet. 2001 Feb; 27(2):167-71.
[Nat Genet. 2001]Bioinformatics. 2002 Sep; 18(9):1167-75.
[Bioinformatics. 2002]Nat Biotechnol. 2002 Aug; 20(8):835-9.
[Nat Biotechnol. 2002]Nat Struct Biol. 1997 Feb; 4(2):122-32.
[Nat Struct Biol. 1997]Nat Genet. 2001 Mar; 27(3):304-8.
[Nat Genet. 2001]Genome Biol. 2002; 3(12):RESEARCH0083.
[Genome Biol. 2002]